Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.

Autor: Goerling U; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Comprehensive Cancer Center, Berlin, Germany., Gauler T; Department of Radiation Oncology, West German Cancer Center, University of Duisburg-Essen Medical School, Essen, Germany., Dietz A; Department of Otolaryngology, Head and Neck Surgery, University Leipzig, Leipzig, Germany., Grünwald V; Interdisciplinary Urooncology, West German Cancer Center, Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, University of Duisburg-Essen Medical School, Essen, Germany., Knipping S; Department of Head and Neck Surgery, Dessau Medical Center, Dessau-Roßlau, Germany., Guntinas-Lichius O; Department of Otorhinolaryngology, Jena University Hospital, Jena, Germany., Frickhofen N; Department of Hematology & Oncology and Palliative Care, HELIOS Dr Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany., Lindeman HW; Department of Hematology & Oncology, KKH Hagen, Hagen, Germany., Fietkau R; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Haxel B; Department of Otolaryngology, Head and Neck Surgery, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany.; Department of Otolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University, Mainz, Germany., Große-Thie C; Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany., Maschmeyer G; Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany., Zipfel M; Department of Internal Medicine III, University Hospital Bonn, Bonn, Germany., Martus P; Institute for Clinical Epidemiology and Applied Biometry, University of Tuebingen, Tuebingen, Germany., Knoedler M; University Cancer Center Leipzig, University Leipzig, Leipzig, Germany., Keilholz U; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Comprehensive Cancer Center, Berlin, Germany., Klinghammer K; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Comprehensive Cancer Center, Berlin, Germany.; Department of Hematology & Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Jazyk: angličtina
Zdroj: Oncology research and treatment [Oncol Res Treat] 2022; Vol. 45 (6), pp. 319-325. Date of Electronic Publication: 2021 Dec 10.
DOI: 10.1159/000521415
Abstrakt: Introduction: CeFCiD was a multicenter phase II study comparing the efficacy of cetuximab (C), 5-flourouracil, and cisplatin with the same regimen adding docetaxel (D) in recurrent/metastatic head and neck cancer. The primary analysis trial did not demonstrate survival benefit from therapy intensification in first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The current analysis of the trial assessed the impact of treatment on quality of life (QoL).
Methods: The European Organization for Research and Treatment of Cancer Quality of life Questionnaire QLQ-C30 and the tumor-specific module for head and neck cancer (QLQ-H&N35) were used to assess QoL at baseline (visit 1), after 2 (visit 3), 4 (visit 5), and 6 (visit 7) cycles of chemotherapy.
Results: Of 180 patients included in this study, 86 patients (47.8%) completed the questionnaires at baseline. Considering selected scores over treatment time, there was no difference in global QoL, dyspnea, swallowing, and speech between the treatment arms in the course. For fatigue, a significant increase from baseline to visit 3 (p = 0.02), visit 5 (p = 0.002), and to visit 7 (p = 0.003) was observed for patients receiving D, cisplatin or carboplatin (P), 5-fluorouracil (F), and C. At the end of chemotherapy, the manifestation of fatigue was similar compared in the 2 treatment arms.
Discussion/conclusion: Therapy intensification not adversely affects selected scores of QoL of patients with recurrent and/or metastatic SCCHN. Nevertheless, fatigue seems to be pronounced in patients treated with D.
(© 2021 S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje